US 2021/0330707 A1 · HIGHLY ACTIVE NK CELL AND USE THEREOF

Abstract

An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof. (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies.

Claims12

Dependent claims

An NK cell having the following characteristics (1) and (2) or a population thereof:

(1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative.
(2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive.

Dependencies are inferred from the claim text.

Facts

Application

16/612,091Filed 11 May 2018

Priority

JP 2017-09528812 May 2017

Published

28 Oct 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 35/02
Antineoplastic agents: specific for leukemia
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61K 40/15
Characterised by the cell type used: natural-killer [NK] cells; Natural-killer T [NKT] cells

Highly active nk cell and use thereof

Life of this patent

Highly active nk cell and use thereof

Life of this patent

Abstract

Claims12